Thirty-five state and regional hospital associations today urged the U.S. Court of Appeals for the District of Columbia Circuit to reverse a district court decision and grant a preliminary injunction to stop a nearly 30% Medicare payment reduction for many hospitals in the 340B Drug Pricing Program while the AHA and other hospital groups challenge the payment cut on appeal. “In evaluating the district court’s denial of a preliminary injunction, this Court must consider the extent to which an injunction is necessary to avert irreparable harm, the balance of the equities, and whether an injunction will serve the public interest,” the associations said in a friend-of-the-court brief. “It is difficult to imagine a case that more obviously satisfies those criteria. The new [Centers for Medicare & Medicaid Services] rule will hobble the ability of hospitals throughout the United States to provide health care to vulnerable populations and, in turn, will jeopardize the lives and health of countless needy patients. For these reasons, amici respectfully urge the Court to reverse the District Court’s decision.”

Related News Articles

Headline
The AHA shared a series of proposals to strengthen rural health care with the Senate Finance Committee for a hearing May 16 titled, “Rural Health Care:…
Headline
The House May 15 passed legislation reauthorizing the Emergency Medical Services for Children Program (H.R. 6960) for an additional five years, providing…
Headline
The House Energy and Commerce Subcommittee on Health May 16 passed a number of bills during a markup session, including AHA-supported legislation. The…
Headline
The RAND Corporation May 13 released its latest hospital pricing report, which focuses on prices paid for care at the hospital and service-line level. In…
Headline
AHA submitted a statement May 8 to the House Ways and Means Committee for a markup session on proposed legislation impacting telehealth access for patients and…
Headline
The Centers for Medicare & Medicaid Services May 3 announced the opening of the comment period for the Inflation Reduction Act’s Medicare Drug Price…